Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction-Reference-Cited by-同舟云学术

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction

Published:2011-09-14 Issue:12 Volume:33 Page:1491-1499
ISSN:1522-9645
Container-title:European Heart Journal
language:en
Short-container-title:

Author:

Lønborg Jacob,Vejlstrup Niels,Kelbæk Henning,Bøtker Hans Erik,Kim Won Yong,Mathiasen Anders B.,Jørgensen Erik,Helqvist Steffen,Saunamäki Kari,Clemmensen Peter,Holmvang Lene,Thuesen Leif,Krusell Lars Romer,Jensen Jan S.,Køber Lars,Treiman Marek,Holst Jens Juul,Engstrøm Thomas

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Link

http://academic.oup.com/eurheartj/article-pdf/33/12/1491/9628589/ehr309.pdf

Reference37 articles.

1. Six-month outcomes in a multinational registry of patients hospitalized with an acute coronary syndrome (the Global Registry of Acute Coronary Events [GRACE]);Goldberg;Am J Cardiol,2004

2. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials;Keeley;Lancet,2003

3. Myocardial reperfusion injury;Yellon;N Engl J Med,2007

4. Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future?;Gersh;JAMA,2005

5. The physiology of glucagon-like peptide 1;Holst;Physiol Rev,2007

Cited by 479 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiac Function, Exercise Capacity and Quality of Life;Cardiac Failure Review;2024-09-11

2. GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management;Nature Metabolism;2024-08-19

3. Therapeutic Potential of Sodium-glucose Co-transporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists for Patients with Acute Coronary Syndrome: A Review of Clinical Evidence;Current Pharmaceutical Design;2024-08

4. The benefits of oral glucose-lowering agents: GLP-1 receptor agonists, DPP-4 and SGLT-2 inhibitors on myocardial ischaemia/reperfusion injury;European Journal of Pharmacology;2024-08

5. Development of the cardioprotective drugs class based on pathophysiology of myocardial infarction: A comprehensive review;Current Problems in Cardiology;2024-05